Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, December 01, 2020
Catalent announced the appointment of Behzad Mahdavi, Ph.D., MBA, as Vice President of Open Innovation, Biologics, Cell and Gene Therapy.
read more
Thursday, February 13, 2020
Catalent announced the appointment of Jim Walter as Vice President of Operations for its Oral and Specialty Delivery business.
read more
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced two senior appointments to further strengthen its global biologics ...
read more
Catalent announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer.
read more
Catalent announced that its Board of Directors has appointed Alessandro Maselli, currently President and Chief Operating Officer, as the company’s next President and Chief Executive Officer, effective July 1, 2022.
read more
Catalent, Inc. announced changes to its operating structure and executive leadership team that went into effect July 1. This new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the ...
read more
Catalent announced it is investing up to $40 million at its manufacturing facility in Winchester, Kentucky.
read more
Monday, February 22, 2021
Catalent recently signed a multi-year commercial supply agreement with Aurinia for LUPKYNIS, a drug to treat adult patients with lupus nephritis.
read more
Catalent will provide support for the development, manufacturing, and clinical supply of Editas Medicine’s current and future portfolio of in vivo CRISPR medicines and engineered cell medicines.
read more
Catalent will expand its Argentinian site in Loma Hermosa, Buenos Aires.
read more
Thursday, September 22, 2022
Catalent, a leader in enabling biopharma, cell, gene, and consumer health partners to optimize the development, launch, and supply of better patient treatments across multiple modalities, announced that it has reached an agreement to acquire Metrics ...
read more
Catalent announced the BSI has awarded Catalent a global accreditation against the international management standards for environment and Occupational Safety.
read more
Cascade Chemistry has been selected to produce the active pharmaceutical ingredient (API) for clinical trial supplies of RBT-9.
read more
Monday, February 22, 2021
Cascade Chemistry announced initiation of construction of new facilities designed to increase the company’s capacity to manufacture APIs under cGMP.
read more
Friday, February 19, 2021
Cascade Chemistry announced initiation of construction of new facilities designed to increase the company’s capacity to manufacture APIs under cGMP.
read more